Literature DB >> 15165499

Safety and efficacy of herbal sedatives in cancer care.

Keith I Block1, Charlotte Gyllenhaal, Mark N Mead.   

Abstract

Insomnia and other sleep disturbances are common in cancer patients. Insomnia is a multifactorial health concern that currently affects at least 1 in 3 cancer patients, and yet most insomnia sufferers do not consult their physician regarding pharmaceutical options for relief. Use of hypnotic drugs (primarily benzodiazepines) is associated with increasing tolerance, dependence, and adverse effects on the central nervous system. While hypnotic drug use declined substantially in the past decade, the use of herbal sedatives appeared to increase. Mostly self-prescribed by lay people, herbal sedatives hold widespread appeal, presumably because of their lower cost and higher margin of safety when compared to pharmaceuticals. Studies of better-known herbal sedatives, notably valerian and kava, showed moderate evidence for both safety and efficacy for valerian while revealing disturbing toxicity concerns for kava. Milder sedatives or anxiolytics in need of clinical study include German chamomile, lavender, hops, lemon balm, and passionflower; St. John's wort may have anxiolytic effects with relevance to sleep. Herb-drug interactions are a possibility for some of these species, including St. John's wort. Although sufficient evidence exists to recommend some of these agents for short-term relief of mild insomnia, long-term trials and observational studies are needed to establish the safety of prolonged use as well as overall efficacy in the context of cancer treatment and management.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15165499     DOI: 10.1177/1534735404265003

Source DB:  PubMed          Journal:  Integr Cancer Ther        ISSN: 1534-7354            Impact factor:   3.279


  10 in total

1.  Sleep aid use during and following breast cancer adjuvant chemotherapy.

Authors:  Tiffany A Moore; Ann M Berger; Paul Dizona
Journal:  Psychooncology       Date:  2011-03       Impact factor: 3.894

Review 2.  The globalization of traditional medicine in northern peru: from shamanism to molecules.

Authors:  Rainer W Bussmann
Journal:  Evid Based Complement Alternat Med       Date:  2013-12-28       Impact factor: 2.629

Review 3.  Complementary and alternative medicine for sleep disturbances in older adults.

Authors:  Nalaka S Gooneratne
Journal:  Clin Geriatr Med       Date:  2008-02       Impact factor: 3.076

Review 4.  Management of cancer-related fatigue.

Authors:  Andrea M Barsevick; Tracey Newhall; Susan Brown
Journal:  Clin J Oncol Nurs       Date:  2008-10       Impact factor: 1.027

5.  Long-Term Chamomile Therapy of Generalized Anxiety Disorder: A Study Protocol for a Randomized, Double-Blind, Placebo- Controlled Trial.

Authors:  Jun J Mao; Qing S Li; Irene Soeller; Kenneth Rockwell; Sharon X Xie; Jay D Amsterdam
Journal:  J Clin Trials       Date:  2014-10-09

Review 6.  Integrative Therapy Use for Management of Side Effects and Toxicities Experienced by Pediatric Oncology Patients.

Authors:  Shana S Jacobs
Journal:  Children (Basel)       Date:  2014-11-14

7.  HERBAL PRODUCT USE BY THE CANCER PATIENTS IN BOTH THE PRE AND POST SURGERY PERIODS AND DURING CHEMOTHERAPY.

Authors:  Sema Koçaşlı; Zehra Demircan
Journal:  Afr J Tradit Complement Altern Med       Date:  2017-01-13

8.  Valerian and valeric acid inhibit growth of breast cancer cells possibly by mediating epigenetic modifications.

Authors:  Fengqin Shi; Ya Li; Rui Han; Alan Fu; Ronghua Wang; Olivia Nusbaum; Qin Qin; Xinyi Chen; Li Hou; Yong Zhu
Journal:  Sci Rep       Date:  2021-01-28       Impact factor: 4.379

Review 9.  Understanding CAM Natural Health Products: Implications of Use Among Cancer Patients and Survivors.

Authors:  Judith M Fouladbakhsh; Lynda Balneaves; Elizabeth Jenuwine
Journal:  J Adv Pract Oncol       Date:  2013-09

Review 10.  Valerian: no evidence for clinically relevant interactions.

Authors:  Olaf Kelber; Karen Nieber; Karin Kraft
Journal:  Evid Based Complement Alternat Med       Date:  2014-06-30       Impact factor: 2.629

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.